OMICS

Spatial OMICS Market Research Report 2023 - Global Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 27, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Spatial transcriptomics, DNA, Chemistry, Gene, Proteomics, Disease, Tissue, Genomics, USD, OMICS, COVID-19, Biomedical Research, Growth, FASP, Workflow, Government, OMIC, RNA, Medical imaging

The "Spatial OMICS Market Size, Share, & Trends Analysis Report By Technology (Spatial Transcriptomics, Spatial Genomics, Spatial Proteomics), By Product, By Workflow, By Sample Type, By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Spatial OMICS Market Size, Share, & Trends Analysis Report By Technology (Spatial Transcriptomics, Spatial Genomics, Spatial Proteomics), By Product, By Workflow, By Sample Type, By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global spatial OMICS market size is expected to reach USD 558.0 million by 2030.
  • The spatial OMICS field originated from hyperplexed imaging; however, key players have shifted toward the development of spatial transcriptomics solutions and products.
  • The development of novel technologies for spatial OMICS is anticipated to create lucrative opportunities for the fields of translational research as well as diagnostics.

MGI Kicks Off ICG-17 in Riga with Launch of DNBSEQ-T7** HotMPS High-Throughput Sequencing Kit* and Spatial Transcriptomics Grant Program

Retrieved on: 
Wednesday, September 7, 2022
Software, Enzyme, COVID-19, Technology, BGI Group, Research, Agriculture, Precision medicine, Science, MUST, Medicine, Twitter, Risk, ICG, RNA transfection, MGI, Automation, ALL, RNA-Seq, Gene expression, DNB, BGI, DNA nanoball sequencing, Woman, Information Systems International Conference, General manager, CID, List of Nobel laureates, LinkedIn, Data analysis, Patent, Latvian Biomedical Research and Study centre, University, WES, Biomedical Research, YouTube, WGS, OMICS, Nucleotide, Chemistry, University of Debrecen, Conference, Stereophonic sound, Knowledge, G400, Fine chemical, Medical imaging, Hydraulic machinery, Genomics

At ICG-17, MGI introduces its new commercial sequencing chemistry HotMPS* and together with BGI STOmics, a spatial transcriptomics grant program.

Key Points: 
  • At ICG-17, MGI introduces its new commercial sequencing chemistry HotMPS* and together with BGI STOmics, a spatial transcriptomics grant program.
  • At the ICG-17 in Riga, BGI STOmics announces a spatial transcriptomics grant program, which will provide 12 Stereo-seq (Spatial Enhanced Resolution Omics-Sequencing) chips (1cm*1cm), sequencing and data analysis to selected projects by researchers across the globe, excluding mainland China.
  • MGI will provide MGI sequencing products for this Grant.
  • **This sequencer is only available in selected countries, and its software has been specially configured to be used in conjunction with MGI's HotMPS sequencing reagents exclusively.

World Pharma ADMET Testing Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 6, 2022
Health, Pharmaceutical, ADME, Partnership, Molecular imaging, COVID-19, Neurotoxicity, NCL, II, Promega, Hepatotoxicity, Application, Research, NLC, Vaccine, Toxicity, Coronavirus, OMICS, Charles River Laboratories, Absorption, Medicine, Nephrotoxicity, CAGR, Therapy, Failure, III, ADMET, Toxicology, Drug discovery, Clinical trial, Acquisition, Drug development, Metabolism, Patient, Pharmaceutical industry, Fine chemical, Technology

The "Pharma ADMET Testing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Testing Type, Technology, and Application" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharma ADMET Testing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Testing Type, Technology, and Application" report has been added to ResearchAndMarkets.com's offering.
  • Thus, the increasing need for ADME testing in drug development boosts the pharma ADMET testing market.
  • Based on technology, the pharma ADMET testing market is segmented into cell culture, high throughput, molecular imaging, and OMICS technology.
  • The COVID-19 pandemic positively impacted the pharma ADMET testing market due to the increased number of researchers across APAC.

Spatial Omics Solutions Market worth $587.2 Million by 2030 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Wednesday, August 10, 2022
Laboratory, Genome, NanoString Technologies, Prevalence, Research, OMICS, Fluorescence, Proteomics, NGS, RNA, ABS, Illumina, Inc., Biology, Genomics, US, Development, Machine learning, MMI, Gene, Cell biology, Technology, Alex Cartana, MIF, DNA, Translational research, CAGR, Diagnosis, RC2, Seminal vesicles, Drug discovery, Income, 10x Genomics, Lists of diseases, Virology, Drug development, AstraZeneca, Miltenyi Biotec, Biomarker, EV, Bruker, Neuroscience, Analysis, Malignancy, Renewable energy, Medical imaging, Microscope, Akoya

According to the latest research by InsightAce Analytic, the global spatial omics solutions market is valued at US$ 232.6 million in 2021, and it is expected to reach US$ 587.2 million by 2030, with a CAGR of 11.18% during the forecast period of 2022-2030.

Key Points: 
  • According to the latest research by InsightAce Analytic, the global spatial omics solutions market is valued at US$ 232.6 million in 2021, and it is expected to reach US$ 587.2 million by 2030, with a CAGR of 11.18% during the forecast period of 2022-2030.
  • The phrase "spatial omics" refers to a group of technologies that allow -omics data to be superimposed on images of tissue.
  • There are several different types of omics studies that are all grouped under the umbrella word "omics."
  • Global Spatial Omics Solutions Market, by Solution Type, 2022-2030 (Value US$ Mn)

Spatial Omics Solutions Market worth $587.2 Million by 2030 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Wednesday, August 10, 2022
Laboratory, Genome, NanoString Technologies, Prevalence, Research, OMICS, Fluorescence, Proteomics, NGS, RNA, ABS, Illumina, Inc., Biology, Genomics, US, Development, Machine learning, MMI, Gene, Cell biology, Technology, Alex Cartana, MIF, DNA, Translational research, CAGR, Diagnosis, RC2, Seminal vesicles, Drug discovery, Income, 10x Genomics, Lists of diseases, Virology, Drug development, AstraZeneca, Miltenyi Biotec, Biomarker, EV, Bruker, Neuroscience, Analysis, Malignancy, Renewable energy, Medical imaging, Microscope, Akoya

According to the latest research by InsightAce Analytic, the global spatial omics solutions market is valued at US$ 232.6 million in 2021, and it is expected to reach US$ 587.2 million by 2030, with a CAGR of 11.18% during the forecast period of 2022-2030.

Key Points: 
  • According to the latest research by InsightAce Analytic, the global spatial omics solutions market is valued at US$ 232.6 million in 2021, and it is expected to reach US$ 587.2 million by 2030, with a CAGR of 11.18% during the forecast period of 2022-2030.
  • The phrase "spatial omics" refers to a group of technologies that allow -omics data to be superimposed on images of tissue.
  • There are several different types of omics studies that are all grouped under the umbrella word "omics."
  • Global Spatial Omics Solutions Market, by Solution Type, 2022-2030 (Value US$ Mn)

SCIEX Launches the Next Generation of Data Independent Acquisition With Zeno SWATH DIA at ASMS 2022

Retrieved on: 
Monday, June 6, 2022
Health, Technology, Nanotechnology, Other Technology, Research, Science, Biotechnology, Biomarker, Precision medicine, Research, Max Planck Institute of Biochemistry, Safety, Mass spectrometry, Francis Crick Institute, Disease, Solution, Health, SWATH, OMICS, Patient, Danaher Corporation, Technology, DHR, NYSE, Medicine, Drug development, Institute, Protein, Medical imaging, Silviculture, SCIEX

SCIEX , a global leader in life science analytical technologies, and a company of Danaher Corporation (NYSE:DHR), launches Zeno SWATH DIA, a significant step forward in biomarker discovery and translation workflows.

Key Points: 
  • SCIEX , a global leader in life science analytical technologies, and a company of Danaher Corporation (NYSE:DHR), launches Zeno SWATH DIA, a significant step forward in biomarker discovery and translation workflows.
  • This means the potential for the development of clinical tests for early detection of disease is vastly increased.
  • The sensitivity of Zeno SWATH DIA also enables large numbers of proteins to be quantified from sample loadings up to 10-fold lower than previous SWATH approaches.
  • With Zeno SWATH DIA we can now do studies that we couldnt do before due to cost alone.

Potential Opportunity Worth USD 2.5 Bn Opening Up in Lab Automation Industry by 2027 - Exclusive Research Published by MarketsandMarkets™

Retrieved on: 
Wednesday, March 2, 2022
Knowledge, Genomics, Satellite navigation, Company, ADAS, Adoption, Intelligence, Research, Machine learning, Automation, Robotics, Information management, Ecosystem, M&A, USD, Growth, GEM, PCR, Écu, SME, Original equipment manufacturer, TAT, Data analysis, Algorithm, Cros, NGS, Workflow, CAGR, GEOS, Technology, Internet service provider, AI, Drug discovery, AR, VR, Video game, Fine chemical, Medical device, Medical imaging, Computer data storage, Risk management, Marketing, OMICS

There is ~USD 6.3 Bn worth of incremental revenue expected within the lab automation space by 2027, with lab workstations, information management SOLUTIONS, e-notebooks, and robotics being the key drivers.

Key Points: 
  • There is ~USD 6.3 Bn worth of incremental revenue expected within the lab automation space by 2027, with lab workstations, information management SOLUTIONS, e-notebooks, and robotics being the key drivers.
  • Adjacent end-use markets hold a potential of over USD 10 Bn in automated lab solutions, with clinical research, clinical diagnostics, and omics research being the major contributors.
  • As automation reduces TAT, helps in minimization of errors and provides reproducible results, it is largely used in clinical testing applications.
  • Bioinformatics, AI, & other digital tools are largely used in clinical settings vs research as former demands data analysis for clinical decision making.

Potential Opportunity Worth USD 2.5 Bn Opening Up in Lab Automation Industry by 2027 - Exclusive Research Published by MarketsandMarkets™

Retrieved on: 
Wednesday, March 2, 2022
Knowledge, Genomics, Satellite navigation, Company, ADAS, Adoption, Intelligence, Research, Machine learning, Automation, Robotics, Information management, Ecosystem, M&A, USD, Growth, GEM, PCR, Écu, SME, Original equipment manufacturer, TAT, Data analysis, Algorithm, Cros, NGS, Workflow, CAGR, GEOS, Technology, Internet service provider, AI, Drug discovery, AR, VR, Video game, Fine chemical, Medical device, Medical imaging, Computer data storage, Risk management, Marketing, OMICS

There is ~USD 6.3 Bn worth of incremental revenue expected within the lab automation space by 2027, with lab workstations, information management SOLUTIONS, e-notebooks, and robotics being the key drivers.

Key Points: 
  • There is ~USD 6.3 Bn worth of incremental revenue expected within the lab automation space by 2027, with lab workstations, information management SOLUTIONS, e-notebooks, and robotics being the key drivers.
  • Adjacent end-use markets hold a potential of over USD 10 Bn in automated lab solutions, with clinical research, clinical diagnostics, and omics research being the major contributors.
  • As automation reduces TAT, helps in minimization of errors and provides reproducible results, it is largely used in clinical testing applications.
  • Bioinformatics, AI, & other digital tools are largely used in clinical settings vs research as former demands data analysis for clinical decision making.

Worldwide Spatial OMICS Industry to 2028 - Featuring 10x Genomics, NanoString Technologies and PerkinElmer Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 3, 2022
Health, Genetics, Lipidomics, Awareness, Growth, Omics, Drug discovery, Government, USD, Workflow, OMICS, Conditional sentence, Clinical trial, Metabolomics, Genomics, Technology, Proteomics, Research, NGS, Epigenomics, CAGR, HMS, Gene, Genome, Incidence, NanoString Technologies, Drug development, Harvard Medical School, Industry, RNA, Genetics, Medical imaging, Nature Methods

Spatial omics combines the molecular scrutiny with spatial data on the cell's localization in the interior of the tissue.

Key Points: 
  • Spatial omics combines the molecular scrutiny with spatial data on the cell's localization in the interior of the tissue.
  • The spatial OMICS market drivers include high applications as diagnostics tools, especially in oncology area.
  • Many emerging spatial OMICS technologies and advancements aid in the growth of the spatial OMICS market.
  • By region, the global spatial OMICS market is divided into Europe, North America, Asia Pacific, Middle East & Africa, and South America.

The Worldwide Omics-Based Clinical Trials Industry is Expected to Reach $49.5 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 21, 2022
Health, Clinical Trials, Biomarker, CAGR, COVID-19, Cancer, Research, Technology, Vaccine, Clinical trial, Biotechnology, Genomics, Adoption, Growth, Death, Industry, Proteomics, Ecosystem, Cros, Drug development, Teaching hospital, Omics, Therapy, USD, Toxicity, OMICS, Prevalence, Lists of countries and territories, Metabolomics, Clinical study design, Drug discovery, Conditional sentence, Coronavirus, Medical imaging, Pharmaceutical industry, Fine chemical

The global omics-based clinical trials market size is anticipated to reach USD 49.5 billion by 2030.

Key Points: 
  • The global omics-based clinical trials market size is anticipated to reach USD 49.5 billion by 2030.
  • The outbreak of coronavirus accelerated the adoption of new approaches, models, and technology in clinical trials, this has positively impacted market growth.
  • Initially, the outbreak has negatively impacted the ecosystem of clinical trials and affected many ongoing studies for numerous indications.
  • There has been an increase in the clinical trials activity with oncology trials attaining historically high levels.